Vir Biotechnology (VIR) Gains from Sales and Divestitures (2018 - 2022)

Vir Biotechnology has disclosed Gains from Sales and Divestitures across 5 years of filings, most recently posting $349496.0 for Q4 2022.

• Gains from Sales and Divestitures for Q4 2022 came in at $349496.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $349496.0 (changed N/A YoY), and the FY2022 annual result was $349496.0, changed N/A from the prior year.
• Gains from Sales and Divestitures came in at $349496.0 for Q4 2022 at Vir Biotechnology, up from $216886.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $2.2 million in Q4 2018 to a low of $52963.0 in Q1 2021.
• The 5-year median for Gains from Sales and Divestitures is $924352.0 (2020), against an average of $1.1 million.
• Across the five-year window, Gains from Sales and Divestitures plunged 95.02% in 2021 and soared 309.5% in 2022, its largest moves.
• Vir Biotechnology's Gains from Sales and Divestitures stood at $2.2 million in 2018, then dropped by 11.63% to $2.0 million in 2019, then decreased by 9.79% to $1.8 million in 2020, then slumped by 95.02% to $89261.0 in 2021, then jumped by 291.54% to $349496.0 in 2022.
• The last three Gains from Sales and Divestitures figures came in at $349496.0 (Q4 2022), $216886.0 (Q1 2022), and $89261.0 (Q3 2021), per Business Quant data.